The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
A Phase I/IIa Clinical Trial of a Recombinant Rho Protein Antagonist in Acute Spinal Cord Injury
Abstract
Multiple lines of evidence have validated the Rho pathway as important in controlling the neuronal response to growth inhibitory proteins after central nervous system (CNS) injury. A drug called BA-210 (trademarked as Cethrin(®)) blocks activation of Rho and has shown promise in pre-clinical animal studies in being used to treat spinal cord injury (SCI). This is a report of a Phase I/IIa clinical study designed to test the safety and tolerability of the drug, and the neurological status of patients following the administration of a single dose of BA-210 applied during surgery following acute SCI. Patients with thoracic (T2-T12) or cervical (C4-T1) SCI were sequentially recruited for this dose-ranging (0.3 mg to 9 mg Cethrin), multi-center study of 48 patients with complete American Spinal Injury Association assessment (ASIA) A. Vital signs; clinical laboratory tests; computed tomography (CT) scans of the spine, head, and abdomen; magnetic resonance imaging (MRI) of the spine, and ASIA assessment were performed in the pre-study period and in follow-up periods out to 1 year after treatment. The treatment-emergent adverse events that were reported were typical for a population of acute SCI patients, and no serious adverse events were attributed to the drug. The pharmacokinetic analysis showed low levels of systemic exposure to the drug, and there was high inter-patient variability. Changes in ASIA motor scores from baseline were low across all dose groups in thoracic patients (1.8±5.1) and larger in cervical patients (18.6±19.3). The largest change in motor score was observed in the cervical patients treated with 3 mg of Cethrin in whom a 27.3±13.3 point improvement in ASIA motor score at 12 months was observed. Approximately 6% of thoracic patients converted from ASIA A to ASIA C or D compared to 31% of cervical patients and 66% for the 3-mg cervical cohort. Although the patient numbers are small, the observed motor recovery in this open-label trial suggests that BA-210 may increase neurological recovery after complete SCI. Further clinical trials with Cethrin in SCI patients are planned, to establish evidence of efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting Recovery: Priorities of the Spinal Cord-Injured Population
Anderson, K. D. (2004) · Journal of Neurotrauma · doi:10.1089/neu.2004.21.1371 · Cited by 2,094
Fitch, M. T., & Silver, J. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2007.05.014 · Cited by 1,007 · cited 1×
“Molecules associated with myelin debris, as well as extracellular matrix molecules in the glial scar, among others have been shown to cause growth cone collapse in injured axons and to inhibit regeneration (Fitch and Silver, 2008; Li et al., 2004; Rowland et al., 2008).”
Axons from CNS neurones regenerate into PNS grafts
Richardson, P. M., McGuinness, U. M., & Aguayo, A. J. (1980) · Nature · doi:10.1038/284264a0 · Cited by 932
Fawcett, J. W., Curt, A., Steeves, J. D., Coleman, W. P., Tuszynski, M. H., Lammertse, D., Bartlett, P. F., Blight, A. R., Dietz, V, Ditunno, J., et al. (2007) · Spinal Cord · doi:10.1038/sj.sc.3102007 · Cited by 882
Self-citationLINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex
Mi, S., Lee, X., Shao, Z., Thill, G., Ji, B., Relton, J., Levesque, M., Allaire, N., Perrin, S., Sands, B., et al. (2004) · Nature Neuroscience · doi:10.1038/nn1188 · Cited by 826
Rowland, J. W., Hawryluk, G. W. J., Kwon, B., & Fehlings, M. G. (2008) · Neurosurgical Focus · doi:10.3171/foc.2008.25.11.e2 · Cited by 816
Self-citationRho Signaling Pathway Targeted to Promote Spinal Cord Repair
Dergham, P., Ellezam, B., Essagian, C., Avedissian, H., Lubell, W. D., & McKerracher, L. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06570.2002 · Cited by 726
Self-citationInactivation of Rho Signaling Pathway Promotes CNS Axon Regeneration
Lehmann, M., Fournier, A., Selles-Navarro, I., Dergham, P., Sebok, A., Leclerc, N., Tigyi, G., & McKerracher, L. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-17-07537.1999 · Cited by 590
Self-citationSchwab, M. E., Kapfhammer, J. P., & Bandtlow, C. E. (1993) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.16.030193.003025 · Cited by 535
The Sygen® Multicenter Acute Spinal Cord Injury Study
Geisler, F. H., Coleman, W. P., Grieco, G., & Poonian, D. (2001) · Spine · doi:10.1097/00007632-200112151-00015 · Cited by 475
Cited by
Ahuja, C. S., Wilson, J. R., Nori, S., Kotter, M. R. N., Druschel, C., Curt, A., & Fehlings, M. G. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.18 · Cited by 2,441
Self-citationTraumatic Spinal Cord Injury—Repair and Regeneration
Ahuja, C. S., Nori, S., Tetreault, L., Wilson, J., Kwon, B., Harrop, J., Choi, D., & Fehlings, M. G. (2017) · Neurosurgery · doi:10.1093/neuros/nyw080 · Cited by 923
Self-citationTraumatic Brain Injuries: Pathophysiology and Potential Therapeutic Targets
Ng, S. Y., & Lee, A. Y. W. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00528 · Cited by 852
From basics to clinical: A comprehensive review on spinal cord injury
Silva, N. A., Sousa, N., Reis, R. L., & Salgado, A. J. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.11.002 · Cited by 814
Recent update on basic mechanisms of spinal cord injury
Quadri, S. A., Farooqui, M., Ikram, A., Zafar, A., Khan, M. A., Suriya, S. S., Claus, C. F., Fiani, B., Rahman, M., Ramachandran, A., et al. (2020) · Neurosurgical Review · doi:10.1007/s10143-018-1008-3 · Cited by 342
Metadata
- Authors
- Fehlings, M. G., Theodore, N., Harrop, J., Maurais, G., Kuntz, C., Shaffrey, C. I., Kwon, B. K., Chapman, J., Yee, A., Tighe, A., & McKerracher, L.
- Venue
- Journal of Neurotrauma
- Publisher
- SAGE Publications
- Published
- 2011-05
- Volume
- 28
- Issue
- 5
- Pages
- 787-796
- ISSN
- 0897-7151 (ISSN-L)
- 1557-9042
- OpenAlex
- W2003453345
- Cited by
- 281
- References
- 31
- FWCI
- 13.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase I/IIa Clinical Trial of a Recombinant Rho Protein Antagonist in Acute Spinal Cord Injury. https://app.cochat.ai/papers/10.1089/neu.2011.1765
- The paper
- Fehlings, M. G., Theodore, N., Harrop, J., Maurais, G., Kuntz, C., Shaffrey, C. I., Kwon, B. K., Chapman, J., Yee, A., Tighe, A., & McKerracher, L. (2011). A Phase I/IIa Clinical Trial of a Recombinant Rho Protein Antagonist in Acute Spinal Cord Injury. Journal of Neurotrauma. https://doi.org/10.1089/neu.2011.1765
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.